WHO/IARC launched the ‘WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention’

The guideline aims to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. The guidelines include recommendations for the general population and for women living with HIV/AIDS and consist of 23 recommendations and 7 good practice statements.

• Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.
• Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population.

Read more and download the guidelines: https://www.who.int/publications/i/item/9789240030824

IARC Handbooks of Cancer Prevention

The guidelines are based on the consensus evaluation of the Working Group as a part of the IARC Handbooks of Cancer Prevention programme. Find more information about the Handbooks here: https://handbooks.iarc.fr/publications/related-publications

Questions and Answers:

Below are some examples of Q&A concerning the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention:

• What are the recommendations using the “screen and treat” approach...?
• What are the recommendations using the “screen-triage-treat” approach...?
• Would the answers to the above questions differ in WLHIV?
• Given the high risk of carcinogenic HPV infections in WLHIV... why is WHO recommending the “screen-triage-treat” approach...?
• We have a VIA based screening system. Should we stop that or use VIA for triaging after HPV?
• What is the price of HPV tests to be considered by countries to have a cost-effective programme?
• What is the false positive and false negative possibility in HPV based testing?

Read more: Questions and Answers